International Clinical Trial: ALLG AMLM28-A3. A randomised study of ambulatory management compared to standard of care for fever related hospitalisation in patients with AML receiving Venetoclax and Azacitidine - a domain of Achieving Durable remissions via Adaptive Pro-survival Targeting in AML (ADAPT)

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ACTRN12626000278336) titled 'ALLG AMLM28-A3. A randomised study of ambulatory management compared to standard of care for fever related hospitalisation in patients with AML receiving Venetoclax and Azacitidine - a domain of Achieving Durable remissions via Adaptive Pro-survival Targeting in AML (ADAPT)' on March 5.

Study Type: Interventional

Study Design: Purpose: Treatment Allocation: Randomised controlled trial

Primary Sponsor: Australasian Leukaemia and Lymphoma Group

Condition: Acute Myeloid Leukaemia Acute Myeloid Leukaemia Cancer - Leukaemia - Acute leukaemia

Intervention: The intervention will involve an ambulatory model of...